Molecular profiling of advanced pancreatic cancer (PC) patients from a phase I/II study using circulating tumor DNA.

4124Background: PC has a poor prognosis with a 5-year survival of 9%. Targeted therapies have yet to demonstrate improved outcomes in this disease. Circulating tumour DNA (ctDNA) may be used as a n...